Keegan M. is a seasoned communications professional currently serving as the Senior Communications Manager at the Society for Immunotherapy of Cancer (SITC), where responsibilities include collaborating with directors to enhance marketing campaigns and engagement. Prior experience includes managerial roles in business development and outreach at Easterseals Southeast Wisconsin, and leadership positions at HEAR Wisconsin, Inc., overseeing operations and marketing strategies. Keegan has also worked in various capacities in media assistance, content management, and grant writing in educational and nonprofit organizations. Academic qualifications include an MBA and multiple degrees in business analytics and professional writing from the University of Wisconsin-Milwaukee, along with studies in English from Marquette University.
Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. sitc_log_color.png Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Currently, SITC has more than 2,000 members who represent 22 medical specialties in 42 countries around the world. Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.